Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMX5N3V)

• Drug Name: 1-(3-(pentafluorosulfanyl)phenyl)propan-2-amine Drug Info
• Synonyms: CHEMBL239434

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 23643874
  TTD Drug ID: DMX5N3V

Molecule-Related Drug Atlas

Drug(s) Targeting 5-HT 1B receptor (HTR1B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[2]
Eletriptan	DMW649X	Migraine	8A80	Approved	[3]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[3]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[3]
Fluphenazine	DMIT8LX	Psychotic disorder	6A20-6A25	Approved	[3]
Naratriptan	DMO50U2	Headache	8A80-8A84	Approved	[4]
Prolixin decanoate	DMMJ1IS	Schizophrenia	6A20	Approved	[3]
Eltoprazine	DMW6C81	Attention deficit hyperactivity disorder	6A05.Z	Phase 3	[5]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[6]
[N-methyl-3H(3)]AZ-10419369	DMSCV02	Mood disorder	6A60-6E23	Phase 1	[7]

Drug(s) Targeting 5-HT 1D receptor (HTR1D)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[8]
Eletriptan	DMW649X	Migraine	8A80	Approved	[3]
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[3]
Frovatriptan	DM7RE8P	Migraine	8A80	Approved	[3]
Sumatriptan	DMVYXR8	Cluster headache	8A81.0	Approved	[9]
Rizatriptan	DMDJMA3	Migraine	8A80	Approved	[10]
Almogran	DM7I64Z	Migraine	8A80	Approved	[11]
Neu-P11	DMIQDFW	Alzheimer disease	8A20	Phase 2	[12]
FKB01MD	DM2O7NM	N. A.	N. A.	Phase 2	[13]
NXN-188	DMMBAIH	Migraine	8A80	Phase 2	[6]

Drug(s) Targeting 5-HT 6 receptor (HTR6)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
LU AE58054	DMWGRQD	Schizophrenia	6A20	Phase 3	[14]
SB-742457	DM6L4ZT	Alzheimer disease	8A20	Phase 3	[15]
AVN 211	DMVB4OS	Schizophrenia	6A20	Phase 2/3	[16]
SYN120	DMDF7XB	Parkinson disease	8A00.0	Phase 2	[17]
AVN 101	DMJFLBC	Alzheimer disease	8A20	Phase 2	[16]
SYN-120	DMPW0UL	Alzheimer disease	8A20	Phase 2	[18]
PF-05212377	DMPVQYR	Alzheimer disease	8A20	Phase 2	[19]
AVN 322	DMK2LGM	Cognitive impairment	6D71	Phase 2	[15]
SAM-531	DMHVJZ6	Alzheimer disease	8A20	Phase 2	[20]
SUVN-502	DMQD753	Alzheimer disease	8A20	Phase 2	[21]

Drug(s) Targeting 5-HT 2B receptor (HTR2B)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[22]
Triflupromazine	DMKFQJP	Nausea	MD90	Approved	[23]
Minaprine	DM0EP7M	Depression	6A70-6A7Z	Approved	[24]
SPN-812	DMTV7XH	Attention deficit hyperactivity disorder	6A05.Z	Phase 4	[25]
Vabicaserin	DM9GZW6	Psychotic disorder	6A20-6A25	Phase 2	[26]
PRX-08066	DMR7H2V	Pulmonary arterial hypertension	BB01.0	Phase 2	[27]
Pyrimidine derivative 29	DMVOYJ8	N. A.	N. A.	Patented	[28]
Pyrimidine derivative 26	DM90WKN	N. A.	N. A.	Patented	[28]
Pyrimidine derivative 23	DM5MLQU	N. A.	N. A.	Patented	[28]
Pyrimidine derivative 25	DM51MFS	N. A.	N. A.	Patented	[28]

Drug(s) Targeting 5-HT 2A receptor (HTR2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metergolin	DMJFP6G	Hyperprolactinaemia	5A60.1	Approved	[22]
ZOTEPINE	DMF3VXA	Anxiety disorder	6B00-6B0Z	Approved	[29]
Iloperidone	DM6AUFY	Schizophrenia	6A20	Approved	[30]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[31]
Lurasidone hydrochloride	DMCVPXO	Schizophrenia	6A20	Approved	[32]
Aniracetam	DMOIFW0	Cerebrovascular ischaemia	8B1Z	Approved	[33]
lumateperone tosylate	DMQ8HOJ	Schizophrenia	6A20	Approved	[34]
Sarpogrelate	DMGLP6S	Diabetic complication	5A2Y	Approved	[35]
Pimavanserin	DMR7IVC	Parkinson disease	8A00.0	Approved	[36]
Zicronapine	DMP8ESD	Schizophrenia	6A20	Phase 3	[37]

Drug(s) Targeting 5-HT 1A receptor (HTR1A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Trazodone	DMK1GBJ	Depression	6A70-6A7Z	Approved	[3]
Buspirone	DMBS632	Anxiety disorder	6B00-6B0Z	Approved	[38]
OPC-34712	DMHG57U	Major depressive disorder	6A70.3	Approved	[39]
Vilazodone	DM4LECQ	Major depressive disorder	6A70.3	Approved	[40]
Flibanserin	DM70DTN	Depression	6A70-6A7Z	Approved	[31]
Gepirone	DMGX5Q0	Major depressive disorder	6A70.3	Approved	[41]
TERTATOLOL	DM2L3D5	Hypertension	BA00-BA04	Approved	[42]
Urapidil	DMD59GI	Hypertension	BA00-BA04	Approved	[43]
Treximet	DMU54QB	Migraine	8A80	Approved	[44]
CM-2395	DMASPWR	Schizophrenia	6A20	Phase 3	[45]

Drug(s) Targeting 5-HT 7 receptor (HTR7)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
RP5063	DMKUE8O	Schizophrenia	6A20	Phase 2	[13]
JNJ-18038683	DMV1T59	Major depressive disorder	6A70.3	Phase 2	[46]
AVN-101	DMOGFNI	Cognitive impairment	6D71	Phase 2	[47]
ATI-9242	DM6GKMU	Schizophrenia	6A20	Phase 1	[48]
PMID30124346-Compound-34TABLE4	DM2G3VE	Attention deficit hyperactivity disorder	6A05.Z	Patented	[49]
PMID30124346-Compound-13TABLE4	DMHTJVA	Attention deficit hyperactivity disorder	6A05.Z	Patented	[49]
Carbamide derivative 2	DMW5GI3	N. A.	N. A.	Patented	[50]
4-oxadiazole derivative 1	DMWFHKR	N. A.	N. A.	Patented	[50]
SB-269970	DM8WTGA	Sleep-wake disorder	7A00-7B2Z	Terminated	[51]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-one	DMM9X0G	Discovery agent	N.A.	Investigative	[52]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
5-HT 1A receptor (HTR1A)	TTSQIFT	5HT1A_HUMAN	Inhibitor	[1]
5-HT 1B receptor (HTR1B)	TTK8CXU	5HT1B_HUMAN	Inhibitor	[1]
5-HT 1D receptor (HTR1D)	TT6MSOK	5HT1D_HUMAN	Inhibitor	[1]
5-HT 2A receptor (HTR2A)	TTJQOD7	5HT2A_HUMAN	Inhibitor	[1]
5-HT 2B receptor (HTR2B)	TT0K1SC	5HT2B_HUMAN	Inhibitor	[1]
5-HT 6 receptor (HTR6)	TTJS8PY	5HT6R_HUMAN	Inhibitor	[1]
5-HT 7 receptor (HTR7)	TTO9X1H	5HT7R_HUMAN	Inhibitor	[1]

References

• [1] The synthesis and biological activity of pentafluorosulfanyl analogs of fluoxetine, fenfluramine, and norfenfluramine. Bioorg Med Chem. 2007 Nov 1;15(21):6659-66.
• [2] Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors. J Neurochem. 1996 Nov;67(5):2096-103.
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [4] Triptans in pregnancy. Ther Drug Monit. 2008 Feb;30(1):5-9.
• [5] Clinical pipeline report, company report or official report of Jazz Pharmaceuticals.
• [6] Company report (NeurAxon)
• [7] 5-HT1B and other related serotonergic proteins are altered in APPswe mutation. Neurosci Lett. 2015 May 6;594:137-43.
• [8] Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor. Mol Pharmacol. 1991 Aug;40(2):143-8.
• [9] Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs. 2001;61(3):317-32.
• [10] An introduction to migraine: from ancient treatment to functional pharmacology and antimigraine therapy. Proc West Pharmacol Soc. 2002;45:199-210.
• [11] Efficacy and tolerability of subcutaneous almotriptan for the treatment of acute migraine: a randomized, double-blind, parallel-group, dose-finding study. Clin Ther. 2001 Nov;23(11):1867-75.
• [12] Clinical pipeline report, company report or official report of Neurim Pharmaceuticals.
• [13] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [14] Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33.
• [15] 5-HT6 receptors and Alzheimer's disease. Alzheimers Res Ther. 2013; 5(2): 15.
• [16] Latrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea. Curr Opin Investig Drugs. 2010 January; 11(1): 80-91.
• [17] Therapeutic strategies for Parkinson disease: beyond dopaminergic drugs. Nat Rev Drug Discov. 2018 Nov;17(11):804-822.
• [18] The Serotonin-6 Receptor as a Novel Therapeutic Target. Exp Neurobiol. 2011 December; 20(4): 159-168.
• [19] PF-05212377 Alzheimer's Disease (Phase 2). Pfizer.
• [20] Activation of 5-HT6 receptors modulates sleep-wake activity and hippocampal theta oscillation. ACS Chem Neurosci. 2013 Jan 16;4(1):191-9.
• [21] Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole Derivatives as 5-HT6 Receptor Ligands. ACS Med Chem Lett. 2010 October 14; 1(7): 340-344.
• [22] Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors. Naunyn Schmiedebergs Arch Pharmacol. 2004 Aug;370(2):114-23.
• [23] Some properties of 5-hydroxytryptamine receptors in the hindquarters of the rat. Br J Pharmacol. 1979 Sep;67(1):79-85.
• [24] Privileged structures: a useful concept for the rational design of new lead drug candidates. Mini Rev Med Chem. 2007 Nov;7(11):1108-19.
• [25] New Insights into the Mechanism of Action of Viloxazine: Serotonin and Norepinephrine Modulating Properties. J Exp Pharmacol. 2020 Aug 25;12:285-300.
• [26] Prediction of Efficacy of Vabicaserin, a 5-HT2C Agonist, for the Treatment of Schizophrenia Using a Quantitative Systems Pharmacology Model.CPT Pharmacometrics Syst Pharmacol.2014 Apr 23;3:e111.
• [27] Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs. 2006 Nov;11(4):609-19.
• [28] Novel serotonin receptor 2 (5-HT2R) agonists and antagonists: a patent review (2004-2014).Expert Opin Ther Pat. 2016;26(1):89-106.
• [29] Current and novel approaches to the drug treatment of schizophrenia. J Med Chem. 2001 Feb 15;44(4):477-501.
• [30] Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
• [31] Radium 223 dichloride for prostate cancer treatment. Drug Des Devel Ther. 2017 Sep 6;11:2643-2651.
• [32] Mullard A: 2010 FDA drug approvals. Nat Rev Drug Discov. 2011 Feb;10(2):82-5.
• [33] Anxiolytic effects of aniracetam in three different mouse models of anxiety and the underlying mechanism. Eur J Pharmacol. 2001 May 18;420(1):33-43.
• [34] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
• [35] Beneficial effects of sarpogrelate hydrochloride, a 5-HT2A receptor antagonist, supplemented with pioglitazone on diabetic model mice. Endocr Res. 2009;34(1-2):18-30.
• [36] Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: comparison with reference dose risperidone, 6mg/day.Schizophr Res.2012 Nov;141(2-3):144-52.
• [37] Clinical pipeline report, company report or official report of Lundbeck.
• [38] Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb Exp Pharmacol. 2005;(169):181-204.
• [39] Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: a role for serotonin 5-HT1A receptors.Pharmacol Biochem Behav.2014 Sep;124:245-9.
• [40] 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4.
• [41] Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. 2008 Aug;33(9):2080-92.
• [42] Synthesis of new derivatives of 8-OH-DPAT: Influence of substitution on the aromatic ring on the pharmacological profile, Bioorg. Med. Chem. Lett. 3(10):2035-2038 (1993).
• [43] Urapidil. A reappraisal of its use in the management of hypertension. Drugs. 1998 Nov;56(5):929-55.
• [44] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [45] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800031127)
• [46] Selective pharmacological blockade of the 5-HT7 receptor attenuates light and 8-OH-DPAT induced phase shifts of mouse circadian wheel running activity. Front Behav Neurosci. 2015 Jan 15;8:453.
• [47] AVN-101: A Multi-Target Drug Candidate for the Treatment of CNS Disorders. J Alzheimers Dis. 2016 May 25;53(2):583-620.
• [48] Pharmacological characteristics of ATI-9242, a Novel Atypical Antipsychotic. FASEB J, April, 2010, 24(Meeting Abstract Supplement),773.12.
• [49] 5-HT1A receptor ligands and their therapeutic applications: review of new patents.Expert Opin Ther Pat. 2018 Sep;28(9):679-689.
• [50] Acyltransferase inhibitors: a patent review (2010-present).Expert Opin Ther Pat. 2015 Feb;25(2):145-58.
• [51] [(3)H]-SB-269970--A selective antagonist radioligand for 5-HT(7) receptors. Br J Pharmacol. 2000 May;130(2):409-17.
• [52] Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 rec... J Med Chem. 2010 Sep 9;53(17):6386-97.